Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Nguyen

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
Gut|November 30, 2019
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 studyCynthia Reichling, Julien Taieb, Valentin Derangere, et al.
Breast Cancer Research and Treatment|March 7, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trialAngeline Ginzac, Ioana Molnar, Xavier Durando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
European Journal of Cancer (Oxford, England : 1990)|March 26, 2022
Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancerSuzette Delaloge, Sylvain Dureau, Véronique D'Hondt, et al.
Gut|November 30, 2019
Artificial intelligence-guided tissue analysis combined with immune infiltrate assessment predicts stage III colon cancer outcomes in PETACC08 studyCynthia Reichling, Julien Taieb, Valentin Derangere, et al.
Breast Cancer Research and Treatment|March 7, 2024
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trialAngeline Ginzac, Ioana Molnar, Xavier Durando, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 28, 2015
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset, Josef Thaler, Richard Greil, et al.
Pageof 2